NCT04124042View on ClinicalTrials.gov

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

XT-150

plasmid DNA

DRUG

Placebo

Placebo is a sterile phosphate-buffered saline

Trial Locations (6)

3004

Alfred Health, Melbourne

5005

University of Adelaide in collaboration with CMAX Clinical Research Pty Ltd, Adelaide

27103

Carolinas Clinical Research Institute, Winston-Salem

90403

Source Healthcare, Santa Monica

91942

eStudySite, La Mesa

94558

Neurovations (Napa Pain Institute), Napa

All Listed Sponsors
lead

Xalud Therapeutics, Inc.

INDUSTRY

NCT04124042 - Efficacy and Safety of XT-150 in Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter